固有免疫分子NLRP3炎性小体在慢性细菌性前列腺炎中的作用

Abstract
Figure/Table
References (20)
Related Citation (1)

Download: PDF (439 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the role of the innate immune molecule NLRP3 inflammasome in chronic bacterial prostatitis (CBP). Methods The 120 cases of CBP patients who admitted to Department of Urology, Affiliated Hospital of Youjiang Medical College (hereinafter referred to as "our hospital") for Nationalities were selected as the research objects from February 2016 to December 2017. The 60 healthy subjects in the same period in our hospital were selected as the control group. CBP patients were treated with trimethoprim plus sulfamethoxazole for 12 weeks. The chronic prostatitis symptom score scale (NIH-CPSI) and routine prostate test were used to evaluate the therapeutic effects of CBP patients. The expression of NLRP3 and its downstream regulatory elements interleukin 1β (IL-1β) and IL-18 were measured by enzyme linked immunosorbent assay in CBP patients. Results Before treatment, the content of NLRP3 inflammatory corpuscule in CBP patients was significantly higher than that in the control group (P ＜ 0.001). Patients were divided into high NLRP3 group and low NLRP3 group (60 cases in each group) according to the median NLRP3 inflammatory body content in CBP patients as the cut-off value. After treatment, pain, urination, quality of life scores and total scores of NIH-CPSI in low NLRP3 group were significantly superior than those in high NLRP3 group (P ＜ 0.05). The clinical response rate of low NLRP3 group was higher than that of high NLRP3 group (P ＜ 0.05). Before treatment, the levels of NLRP3, IL-1β and IL-18 in both groups were significantly higher than those in healthy subjects (P ＜ 0.05). After treatment, the above indexes were significantly decreased in both groups, and the reduction in low NLRP3 group were significantly greater than high NLRP3 group (P ＜ 0.05). After treatment, there was no significant difference in leukocyte and lecithin counts between the two groups (P > 0.05), and no significant adverse reactions were observed in both groups during the treatment. Conclusion The change of NLRP3 inflammasome content is a potential factor that affects the therapeutic effect of CBP. Targeting the NLRP3 inflammasome level can improve the clinical efficacy of CBP.

Key words： Chronic bacterial prostatitis Nod-like receptor protein 3 Inflammasome

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Tao1 HUANG Huawu1 ZENG Yonglong2 GUO Ziwei2 XIE Qiuyu2

Cite this article:

HE Tao1 HUANG Huawu1 ZENG Yonglong2 GUO Ziwei2 XIE Qiuyu2. Role of the innate immune molecule NLRP3 inflammasome in chronic bacterial prostatitis[J]. 中国医药导报, 2019, 16(10): 157-161.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I10/157

[1] Rees J，Abrahams M，Doble A，et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome：a consensus guideline [J]. BJU Int，2015，116（4）：509-525.
[2] Murphy SF，Schaeffer AJ，Done JD，et al. Commensal bacterial modulation of the host immune response to ameliorate pain in a murine model of chronic prostatitis [J]. Pain，2017，158（8）：1517-1527.
[3] Coll RC，Robertson AAB，Chae JJ，et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases [J]. Nature Medicine，2015，21（3）：248.
[4] Jo EK，Kim JK，Shin DM，et al. Molecular mechanisms regulating NLRP3 inflammasome activation [J]. Cell Mol Immunol，2016，13（2）：148.
[5] Zhou Q，Zhang L，Feng C. Wogonoside ameliorates carrageenan-induced chronic nonbacterial prostatitis in rats [J]. Int J Clin Exp Med，2017，10（12）：16203-16209.
[6] 那彦群，叶章群，孙光.2011版中国泌尿外科疾病诊断治疗指南[M].北京：人民卫生出版社，2011.
[7] Gao J，Zhang X. PS-08-007 Relationships between intravaginal ejaculatory latency time and national institutes of health-chronic prostatitis symptom index in the four types of premature ejaculation syndromes：A large observational study in China [J]. J Sex Med，2017，14（4）：e133.
[8] Wagenlehner FME，van Till JWO，Houbiers JGA，et al. Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome：an adaptive double-blind，randomized controlled trial [J]. Urology，2017，103：191-197.
[9] Xie Q，Shen WW，Zhong J，et al. Lipopolysaccharide/adenosine triphosphate induces IL-1β and IL-18 secretion through the NLRP3 inflammasome in RAW264. 7 murine macrophage cells [J]. Int J Mol Med，2014，34（1）：341-349.
[10] Misawa T，Takahama M，Kozaki T，et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome [J]. Nat Immunol，2013，14（5）：454-460.
[11] Heneka MT，Kummer MP，Stutz A，et al. NLRP3 is activated in Alzheimer/'s disease and contributes to pathology in APP/PS1 mice [J]. Nature，2013，493（7434）：674-678.
[12] Haneklaus M，O’Neill LAJ，Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation：recent developments [J]. Curr Opin Immunol，2013， 25（1）：40-45.
[13] Perletti G，Marras E，Wagenlehner FM，et al. Antimicrobial therapy for chronic bacterial prostatitis [J]. Cochrane Database Syst Rev，2013，8（12）：CD009071.
[14] Boehm BJ，Colopy SA，Jerde TJ，et al. Acute bacterial inflammation of the mouse prostate [J]. The Prostate，2012， 72（3）：307-317.
[15] Hughes MM，O′Neill L. Metabolic regulation of NLRP3 [J]. Immunological Reviews，2018，281（1）：88-98.
[16] Christ A，Günther P，Mar L，et al. Western diet triggers NLRP3-dependent innate immune reprogramming [J]. Cell，2018，172（1-2）：162.
[17] Li Y，Pan Y，Gao L，et al. Naringenin protects against acute pancreatitis in two experimental models in mice by NLRP3 and Nrf2/HO-1 pathways [J]. Mediators Inflamm，2018，2018（3）：1-13.
[18] Jr CL，Maile R，Jones SW，et al. HMGB1/IL-1β complexes in plasma microvesicles modulate immune responses to burn injury [J]. PLoS One，2018，13（3）：e0 195 335.
[19] Wada T，Toma T，Miyazawa H，et al. Longitudinal analysis of serum interleukin-18 in patients with familial Mediterranean fever carrying MEFV mutations in exon 10 [J]. Cytokine，2018，104：143-146.
[20] Hahn AM，Myers JD，McFarland EK，et al. Interleukin-driven insulin-like growth factor promotes prostatic inflammatory hyperplasia [J]. J Pharmacol Exp Ther，2014， 351（3）：605-615.